Lung Cancer
A Phase III, Randomized, Double-Blind, Multicenter, Global Study of Rilvegostomig in Combination with Chemotherapy for First-line Treatment of Patients with Metastatic Non-squamous Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03). (D702FC00001)
- Details
ClinicalTrials.gov ID:
NCT06627647
Diagnosis Type:
NA
USOR Number:
- Address
,
P: